112 related articles for article (PubMed ID: 11021899)
1. High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-oesophageal reflux disease (GERD). Swedish multi-centre group in primary health care.
Brun J; Sörngård H
Fam Pract; 2000 Oct; 17(5):401-4. PubMed ID: 11021899
[TBL] [Abstract][Full Text] [Related]
2. Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
Galmiche JP; Zerbib F; Ducrottè P; Fournet J; Rampal P; Avasthy N; Humphries TJ
Aliment Pharmacol Ther; 2001 Sep; 15(9):1343-50. PubMed ID: 11552904
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
[TBL] [Abstract][Full Text] [Related]
4. Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy.
Bohmer CJ; Niezen-de Boer MC; Klinkenberg-Knol EC; Tuynman HA; Voskuil JH; Devillé WL; Meuwissen SG
Am J Gastroenterol; 1997 Sep; 92(9):1475-9. PubMed ID: 9317066
[TBL] [Abstract][Full Text] [Related]
5. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.
Talley NJ; Lauritsen K; Tunturi-Hihnala H; Lind T; Moum B; Bang C; Schulz T; Omland TM; Delle M; Junghard O
Aliment Pharmacol Ther; 2001 Mar; 15(3):347-54. PubMed ID: 11207509
[TBL] [Abstract][Full Text] [Related]
6. Effect of wu chu yu tang on gastroesophageal reflux disease: Randomized, double-blind, placebo-controlled trial.
Shih YS; Tsai CH; Li TC; Yu CJ; Chou JW; Feng CL; Wang KT; Lai HC; Hsieh CL
Phytomedicine; 2019 Mar; 56():118-125. PubMed ID: 30668332
[TBL] [Abstract][Full Text] [Related]
7. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Bautista J; Fullerton H; Briseno M; Cui H; Fass R
Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
[TBL] [Abstract][Full Text] [Related]
8. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group.
Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir DG; Gillon KR; Peacock RA; Fulton C
BMJ; 1999 Feb; 318(7182):502-7. PubMed ID: 10024259
[TBL] [Abstract][Full Text] [Related]
11. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease.
Ofman JJ; Dorn GH; Fennerty MB; Fass R
Aliment Pharmacol Ther; 2002 Feb; 16(2):261-73. PubMed ID: 11860409
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
Foocharoen C; Chunlertrith K; Mairiang P; Mahakkanukrauh A; Suwannaroj S; Namvijit S; Wantha O; Nanagara R
Rheumatology (Oxford); 2017 Feb; 56(2):214-222. PubMed ID: 27179107
[TBL] [Abstract][Full Text] [Related]
13. Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial).
Waghray A; Waghray N; Perzynski AT; Votruba M; Wolfe MM
Dig Dis Sci; 2019 Jan; 64(1):158-166. PubMed ID: 30094626
[TBL] [Abstract][Full Text] [Related]
14. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
15. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial.
Lind T; Havelund T; Lundell L; Glise H; Lauritsen K; Pedersen SA; Anker-Hansen O; Stubberöd A; Eriksson G; Carlsson R; Junghard O
Aliment Pharmacol Ther; 1999 Jul; 13(7):907-14. PubMed ID: 10383525
[TBL] [Abstract][Full Text] [Related]
16. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease.
Fass R; Ofman JJ; Gralnek IM; Johnson C; Camargo E; Sampliner RE; Fennerty MB
Arch Intern Med; 1999 Oct; 159(18):2161-8. PubMed ID: 10527293
[TBL] [Abstract][Full Text] [Related]
18. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors for response to treatment and recurrence of uncomplicated symptomatic gastroesophageal reflux in ambulatory care medicine].
Bommelaer G; Caekaert A; Barthelemy P
Presse Med; 2002 Sep; 31(30):1402-6. PubMed ID: 12378973
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
van Zyl J; van Rensburg C; Vieweg W; Fischer R
Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
